Cargando…
Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194813/ https://www.ncbi.nlm.nih.gov/pubmed/32361169 http://dx.doi.org/10.1016/j.mehy.2020.109792 |
| _version_ | 1783528408589795328 |
|---|---|
| author | Javor, S. Salsano, A. |
| author_facet | Javor, S. Salsano, A. |
| author_sort | Javor, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7194813 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71948132020-05-02 Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? Javor, S. Salsano, A. Med Hypotheses Article Elsevier Ltd. 2020-08 2020-04-25 /pmc/articles/PMC7194813/ /pubmed/32361169 http://dx.doi.org/10.1016/j.mehy.2020.109792 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Javor, S. Salsano, A. Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title | Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title_full | Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title_fullStr | Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title_full_unstemmed | Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title_short | Why not consider an endothelin receptor antagonist against SARS‐CoV‐2? |
| title_sort | why not consider an endothelin receptor antagonist against sars‐cov‐2? |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194813/ https://www.ncbi.nlm.nih.gov/pubmed/32361169 http://dx.doi.org/10.1016/j.mehy.2020.109792 |
| work_keys_str_mv | AT javors whynotconsideranendothelinreceptorantagonistagainstsarscov2 AT salsanoa whynotconsideranendothelinreceptorantagonistagainstsarscov2 |